<DOC>
	<DOCNO>NCT01946061</DOCNO>
	<brief_summary>Patients advance gastric cancer show poor prognosis . Only 81 % patient could undergo curative surgery . In , 60 % patient would survive 5 year surgery . As result , role chemotherapy increase . In ACTS-GC trial , S-1 adjuvant therapy D2 gastrectomy increase overall survival rate advance gastric cancer patient . However , subgroup analysis show S-1 adjuvant therapy insufficient patient stage III IV ( accord AJCC 6th criterion ) gastric cancer . In addition , CLASSIC trial demonstrate oxaliplatin plus capecitabine adjuvant therapy could increase disease-free survival D2 gastrectomy advance gastric cancer patient . Notwithstanding trial , optimal adjuvant regimen advance gastric cancer establish . We aim evaluate efficacy S-1 plus oxaliplatin adjuvant chemotherapy D2 gastrectomy stage III ( accord AJCC 7th criterion ) gastric cancer patient .</brief_summary>
	<brief_title>A Phase II Trial Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Locally Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age , 19 75 Histologically proven advance gastric cancer R0 resection D2 gastrectomy Stage III ( accord AJCC 7th criterion ) ECOG status 0 2 Malignancy history gastric cancer Previous chemotherapy history gastric cancer Previous radiotherapy history gastric cancer Pregnancy breast milk feed Grade 3 neuropathy Active infection Severe hepatic dysfunction Severe renal dysfunction Severe bone marrow dysfunction Significant neurologic psychologic disease Inadequate condition receive chemotherapy due significant systemic disease Patients receive drug interact S1</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Oxaliplatin , S-1 , Gastric cancer , Adjuvant chemotherapy</keyword>
</DOC>